Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide.

ABSTRACT:

Background

Arsenic trioxide [ATO, inorganic arsenite (iAs^III) in solution] plays an important role in the treatment of acute promyelocytic leukemia (APL). However, the long-term adverse effects (AEs) and the retention of arsenic among APL patients are rarely reported. In this study, we focused on arsenic methylation metabolism and its relationship with chronic hepatic toxicity, as we previously reported, among APL patients who had finished the treatment of ATO.

Methods

A total of 112 de novo APL patients who had completed the ATO-containing treatment were enrolled in the study. Arsenic species [iAs^III, inorganic arsenate (iAs^V), and their organic metabolites, monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA)] in patients' plasma, ur

SUBMITTER: Zheng Y 

PROVIDER: S-EPMC7866431 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature